Plain-English translation of NCT05255302 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing how long patients with advanced lung cancer should continue taking pembrolizumab after their first 6 months of combination and immunotherapy. The study will compare two approaches: continuing pembrolizumab (with or without additional , depending on cancer type) versus stopping treatment and being monitored closely. The goal is to find the best balance between controlling cancer and reducing unnecessary medication exposure.
Currently, doctors are uncertain whether continuing this medication after initial treatment helps patients live longer, or whether careful monitoring alone is enough after the cancer has been controlled. This trial will help answer that question and potentially spare patients from prolonged treatment if it is not needed.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive 6 months of combined with pembrolizumab (a type of immunotherapy). After that initial treatment, if your cancer is controlled, you will be randomly assigned to one of two groups: one group continues taking the medication (possibly with additional depending on cancer type) for up to 2 years, while the other group stops treatment and is monitored with regular scans and visits. You will have scheduled clinic visits, blood tests, and imaging scans throughout the study to track your health and cancer status.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
France